Non-drug treatment of non-alcoholic fatty liver disease: evaluation of effectiveness with ultrasound steatometry
https://doi.org/10.33667/2078-5631-2020-10-38-42
Abstract
Objective. Evaluation of the effectiveness of non-drug treatment in patients with non-alcoholic fatty liver disease using the method of quantitative ultrasound steatometry.
Material and methods. We examined 118 patients aged 18–75 years, including 52 (44 %) men and 66 (56 %) women using a single diagnostic algorithm of four stages: questioning and collecting complaints, assessing the quality of life, clinical examination, non-invasive bioimpedansometry, followed by assessment of fat mass index, ultrasound examination of the liver in the B-mode, quantitative ultrasound steatometry by evaluating the attenuation coefficient of the ultrasonic wave. Individual non-drug therapy is prescribed to patients in the form of an individual program of therapeutic nutrition and physical activity. A dynamic assessment of the decrease in the proportion of adipose tissue and the severity of fatty liver infiltration was carried out at points of 6, 12, 18, 24 months. A liver biopsy followed by histological analysis on an SAF scale was performed in 32 patients.
Results. To assess the effectiveness of non-drug treatment in patients, a tendency of reducing the proportion of fat content and the severity of fatty infiltration in the liver was observed. All patients were divided into two groups according to their level of compliance with the prescribed treatment. Decrease in the proportion of adipose tissue in patients with a high level of compliance – up to 76.2 %, in patients with a low level of compliance – up to 89.1 % of the initial values. Decrease in fatty liver infiltration in patients with a high level of compliance – up to 80.2 %, in patients with a low level of compliance – up to 92.1 % of the initial one.
Conclusion. Ultrasound steatometry is an informative method for non-alcoholic fatty liver disease screening. The correlation of quantitative ultrasound diagnostics data for steatosis with a biopsy at stage S0 corresponds to r = 0.85; at stage S1 r = 0.72, at S2 r = 0.73, at stage S3 corresponds to r = 0.84, which indicates the high informativity of this method.
About the Authors
D. Yu. Venidiktova
Smolensk State Medical University
Russian Federation
Russian Federation
Smolensk
A. V. Borsukov
Smolensk State Medical University
Russian Federation
Russian Federation
Smolensk
References
1. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–609.
2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64 (6): 1388–402. DOI: 10.1016/j.jhep.2015.11.004.
3. La Brecque, Douglas R, etc. World Gastroenterology Organisation Global Guidelines. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology: July 2014. – Volume 48. – Issue 6. – P. 467–473.
4. Schwenzer N. F., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance // J Hepatol 2009; 51: 433–45.
5. Simona Leoni, Francesco Tovoli, Lucia Napoli, Ilaria Serio, Silvia Ferri, Luigi Bolondi. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14; 24 (30): 3361–3373.
6. Yada N, Tamaki N, Koizumi Y, Hirooka M, Nakashima O, Hiasa Y, Izumi N, Kudo M.: Diagnosis of fibrosis and activity by a combined use of strain and shear wave imaging in patients with liver disease. Digest Dis, 2017; 35(6): 515–520. DOI: 10.1159/000480140.
7. Балукова Е. В., Барышникова Н. В., Белоусова Л. Н. Неалкогольная жировая болезнь печени: современное состояние проблемы // Фарматека. 2016; 2: 63–8.
8. Борсуков А. В., Венидиктова Д. Ю. Ультразвуковая диагностика стеатоза печени: разработка новой методики количественной оценки патологического процесса // Медицинский алфавит. 2017. 19. С. 47–51.
9. Ивашкин В. Т., Маевская М. В., Жаркова М. С. и др. Алгоритмы диагностики и лечения в гепатологии. Москва. МЕДпресс-информ. 2016. С. 155.
10. Кошурникова А. С., Лукина Е. В. Ожирение и метаболический синдром: вопросы диагностики, профилактики и лечения // Лечащий врач. 2017. № 10. С. 66.
Review
For citations:
Venidiktova D.Yu., Borsukov A.V. Non-drug treatment of non-alcoholic fatty liver disease: evaluation of effectiveness with ultrasound steatometry. Medical alphabet. 2020;(10):38-42. (In Russ.) https://doi.org/10.33667/2078-5631-2020-10-38-42
Views:
458
Email this article 